388 results about "Biopharmaceutical" patented technology

The invention discloses a site for stably expressing protein in a CHO cell gene NW023276806.1 and application of the site, and belongs to the technical field of biological genes. The site belongs to a fixed position in a CHO cell genome, different protein genes are introduced based on a micro-homologous end connection mechanism through a CRISPR / Cas9 tool, and stable expression is carried out. By adopting a site-specific integration method, a target gene is integrated to a stable expression area in a site-specific manner, repeated high-expression monoclonal screening is effectively avoided, and an MMEJ mechanism is introduced to integrate a donor fragment, so that the research and development time for constructing a stable expression cell strain in biological pharmacy can be effectively shortened, and the cost is reduced.

The invention provides a biopharmacy downstream process optimization method and system based on machine learning. The method comprises the following steps: acquiring process parameters, process parameters and key quality attributes from a historical production process; preprocessing the technological parameters, the process parameters and the key quality attributes, performing feature construction, and selecting feature data; training a plurality of pre-acquired machine learning models based on the feature data, identifying key process parameters, evaluating the trained machine learning models according to a preset dimension, and selecting at least one optimal machine learning model according to an evaluation result; and performing parameter combination based on the key process parameters and a preset constraint range, inputting the combined parameters into at least one optimal machine learning model, and selecting a key process parameter combination meeting a preset quality standard according to an output result. According to the method, the problem that the key quality attributes are difficult to accurately predict and optimize in the existing biopharmacy downstream process is solved.

The invention belongs to the technical field of biological medicine, and particularly relates to a novel deuterated JAK2 inhibitor or pharmaceutically acceptable salt thereof. Compared with the prior art, the compound or the pharmaceutically acceptable salt thereof provided by the invention has better JAK2 inhibition activity, and the JAK2 inhibition target selectivity of the compound or the pharmaceutically acceptable salt thereof is obviously superior to that of the existing compound, so that the compound or the pharmaceutically acceptable salt thereof has better druggability.

The invention belongs to the technical field of biological pharmacy, and relates to a method for preparing tremella aurantialba polyphenol by utilizing tremella aurantialba TA58.21 fungus chassis cell fermentation, which comprises the following steps: adding a cooked soybean meal culture medium and a tremella aurantialba seed solution into a fermentation tank, introducing sterile oxygen, controlling the stirring rotating speed of the fermentation tank and the culture temperature to be 25-30 DEG C, continuously culturing for 5-8 days, and when the fermentation liquor becomes red, stopping the fermentation; when a large amount of foam is generated, closing an exhaust valve, keeping the tank pressure at 0.1 MPa, increasing the fermentation temperature to 50 DEG C, continuing to culture for 24 hours, increasing the stirring rotating speed of the fermentation tank, heating the fermentation liquor to 80-90 DEG C, keeping the temperature for 4-8 hours, stopping stirring, continuing to heat to 120 DEG C, and keeping the temperature for 30 minutes; centrifuging the fermentation liquor to remove precipitates and mycelia; collecting supernate, and pre-treating macromolecular substances and thallus fragments; collecting permeate liquid, and intercepting through a nanofiltration membrane to obtain a concentrated solution; and carrying out spray drying or freeze drying treatment on the concentrated solution to obtain a high-purity product. According to the invention, the tremella aurantialba polyphenol product with good water solubility, heat resistance, acid resistance and molecular weight of less than 10000 Da can be obtained.

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-6, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-6 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, analgesia, lactation, breast cancer, lung cancer, uterine fibroids, coagulation, etc.

The invention discloses a dust-free environment purification method for biological pharmacy. Comprising the following steps: constructing three layers of metal filter screens, realizing particle interception through a conical micro-column array, an Al2O3 / TiO2 composite ceramic layer and a diamond-like carbon film, fixing lysozyme by adopting a crystal face regulated ZIF-8 crystal, and realizing dual inactivation of microorganisms by combining dielectric barrier discharge of a spiral plasma channel. The electrostatic adsorption HEPA filter paper adopts a BaTiO3-graphene quantum dot composite electret substrate, and a TiO2 / graphene heterojunction catalytic layer is decomposed by a Pt-Co bimetallic nanocluster and a photocatalysis-plasma-ozone-thermocatalysis quadruple oxidation system; and 0.1 mu m organic aerosol triggers graded reverse pulse cleaning based on differential pressure integration and a particle concentration threshold value, and the honeycomb flow guide structure drives a shutter and a gradient density sintering metal flow guide plate through piezoelectric ceramics to maintain laminar flow uniformity. According to the scheme, the limitation of a traditional technology is broken through, the purification efficiency of 0.1 micron particles is improved, and a high-stability solution is provided for a biopharmaceutical clean room.

The invention relates to the field of biological medicine preparation, and particularly provides liraglutide precursor peptide tandem recombinant fusion protein, polynucleotide, recombinant expression plasmid, engineered host cell and a method for preparing target polypeptide. The recombinant fusion protein is fusion peptide-target polypeptide-(linker peptide-target polypeptide) n from the N terminal to the C terminal, n is a positive integer from 4 to 6, the fusion peptide is SEQ ID NO.1, the target polypeptide is liraglutide precursor peptide, the linker peptide comprises a spacer peptide and a protease restriction enzyme cutting site, the spacer peptide is SEQ ID NO.2, the isoelectric point of the recombinant fusion protein is 4.6-4.7, and the average hydrophilic value is-0.780--0.765. The proportion of the target polypeptide in the recombinant fusion protein is high, use of solvents under extreme conditions is avoided in the production process, the enzyme digestion efficiency is high, and the product purity and yield are high.

The invention relates to the field of computational biology and bioinformatics, in particular to an RNA (Ribonucleic Acid) sequence screening and promoter function predicting and screening method based on machine learning, which comprises the following steps of: firstly, adopting a novel sequence algorithm based on a sliding window and a position weight matrix, and combining technologies such as k-mer frequency analysis and conservative motif recognition; candidate RNA sequences are efficiently identified from genomic sequences. Then, an integrated prediction model fusing deep learning and traditional machine learning is established, and multi-dimensional information such as sequence features, structural features, functional features and evolution features is extracted; and carrying out batch prediction on the candidate RNA sequences, outputting a function intensity score and providing credibility evaluation. And finally, screening an RNA sequence with an optimal prediction result based on a multi-objective optimization strategy, and designing an experimental verification scheme. According to the method, the prediction accuracy and the screening efficiency are improved, the experiment cost can be remarkably reduced, and an efficient promoter screening tool is provided for the fields of synthetic biology, gene therapy, biological pharmacy and the like.

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-8, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-8 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, breast cancer, lung cancer, analgesia, lactation, uterine fibroids, coagulation, etc.

The invention relates to the field of biological medicine preparation, and particularly provides canagliflozin precursor peptide tandem recombinant fusion protein, polynucleotide, recombinant expression plasmid, engineered host cell and a method for preparing target polypeptide. The recombinant fusion protein is a fusion peptide-target polypeptide-(linker peptide-target polypeptide) n from an N terminal to a C terminal, n is a positive integer of 4-6, the fusion peptide is SEQ ID NO.1 or SEQ ID NO.2, the target polypeptide is a canagliptin precursor peptide, the linker peptide comprises a spacer peptide and a protease restriction enzyme cutting site, the spacer peptide is SEQ ID NO.3, the isoelectric point of the recombinant fusion protein is 5.5-6.5, and the average hydrophilic value is-0.85--0.96. The invention creatively provides a method for preparing the canagliflozin precursor peptide by using a gene recombination technology, the proportion of the target polypeptide in the recombinant fusion protein is high, the use of a solvent under extreme conditions is avoided in the production process, the enzyme digestion efficiency is high, and the product purity and yield are high.

The present invention belongs to the field of biopharmaceuticals and specifically relates to a composition for detoxifying alcohol and preventing hangovers and its preparation method, comprising the following steps: 1) adding a portion of yeast extract to purified water to obtain solution A, adding curcumin to anhydrous ethanol to obtain solution B, and mixing solution A and solution B to obtain a mixed solution; 2) adjusting the pH of the mixed solution to 5-6; 3) placing the mixed solution in a -25°C cold trap and allowing it to stand for 16-32 hours until crystals precipitate; 4) filtering at 4°C to obtain a filter cake and a filtrate; 5) pulverizing the filter cake to obtain a crystalline powder; and 6) uniformly mixing the crystalline powder, another portion of yeast extract, dihydroquercetin, and excipients, and then tableting to obtain the composition for detoxifying alcohol and preventing hangovers. The present invention utilizes a complex formed by precipitating the yeast extract and curcumin cocrystals, which expands the application range of the composition and improves the solubility and bioavailability of curcumin.

As a series of viscosity-reducing and stabilizing formulations for high-concentration protein formulations, they are finely tuned to significantly reduce the viscosity of high-concentration biopharmaceuticals and increase their stability. Viscosity-reducing and stabilizing formulations can be used for high-concentration biopharmaceutical products and have significant potential to improve stability during manufacturing and storage, thereby increasing the feasibility of high-concentration biopharmaceutical products.

The invention relates to an SR-B1 targeted polypeptide compound and application thereof in preparation of antitumor drugs and immunotherapy sensitizers, and belongs to the technical field of biological drug manufacturing. In order to solve the problems that an existing PD-L1 inhibitor is single in action mechanism and immune system dysfunction is easily caused, the invention provides an SR-B1 targeted polypeptide compound which is composed of SR-B1 targeted polypeptide and Resiquimod. The SR-B1 targeting polypeptide comprises an SR-B1 targeting peptide fragment, a self-assembly peptide fragment and a hydrophobic molecule which are connected in sequence. The SR-B1 targeting polypeptide can recognize overexpressed SR-B1 in tumor cells, block cholesterol uptake, inhibit tumor progression and inhibit expression of PD-L1 at the same time. The polypeptide compound accurately delivers Resiquimod to a tumor site, anti-tumor immune response is activated, and sensitivity of tumor immunotherapy is greatly enhanced through combination of cholesterol metabolism regulation and immunotherapy.

The application discloses application of O-acyl-alpha-hydroxy acid compounds in weight loss and lipid reduction, and belongs to the fields of biological medicine manufacturing, biological medicine use and functional food development. The O-acyl-alpha-hydroxy acid compounds can inhibit weight growth of high-fat diet-induced obese model mice and reduce body fat. Compared with GLP-1 receptor weight loss drugs which achieve the effect of reducing weight by inhibiting appetite, the O-acyl-alpha-hydroxy acid compounds are not dependent on appetite inhibition, and can reduce side effects such as gastrointestinal discomfort and muscle loss caused by inhibiting appetite. When combined or sequentially administered with GLP-1 drugs, the O-acyl-alpha-hydroxy acid compounds can maintain or enhance the weight loss effect while improving the side effects caused by GLP-1, and can prevent the risk of significant weight rebound after stopping GLP-1 by maintaining body weight. The application provides a safe and effective new strategy for weight loss and lipid reduction.

Provided are poly(ethylene glycol)-polyoxazoline (PEOZ) copolymers. In some cases, the PEOZ polymer has a repeat unit of structure –CH2N(C(O)R)CH2CH2OCH2CH2–. The PEOZ copolymers can be used in a variety of applications, e.g., to increase the solubility of various compounds, such as drugs, dyes and biopharmaceuticals. Also provided are methods of making the PEOZ copolymers, which in some cases can generate monodisperse compositions of PEOZ copolymers.

The present application relates to the technical field of biopharmaceuticals, and in particular, polypeptides or derivatives thereof, pharmaceutically acceptable salts thereof based on artificial intelligence design and applications thereof are provided, wherein the amino acid sequence of the polypeptides is shown as SEQ ID NO:1.The polypeptides or derivatives thereof, pharmaceutically acceptable salts thereof can simultaneously bind to PD-1 and CTLA-4, can effectively block the binding between PD-1 and CTLA-4 and their ligands respectively, release the inhibition of immune checkpoint proteins PD-1 and CTLA-4 on immune cells, and significantly enhance the anti-tumor immune response of the body. The polypeptides or derivatives thereof, pharmaceutically acceptable salts thereof can be used for detecting PD-1 and / or CTLA-4, and can also be used for treating or preventing diseases related to PD-1 and / or CTLA-4.

Disclosed is a method implemented for outputting model(s) for developing or operating a process for a CGT. The method includes receiving, storing, and accessing data items; determining attributes of the data items; selecting one or more machine learning models based on the attributes; accessing one or more mechanistic models; integrating the one or more machine learning models with the one or more mechanistic models to obtain one or more integrated models; selecting one or more predictive models from the one or more machine learning models, the one or more mechanistic models, and the one or more integrated models; applying the one or more predictive models to the data items; adjusting one or more values of one or more parameters of the one or more predictive models to reduce uncertainty in model prediction; and outputting the one or more predictive models with the one or more adjusted values.

The invention discloses a biopharmaceutical high-pressure sterilization device, and belongs to the field of sterilization devices.The biopharmaceutical high-pressure sterilization device comprises a sterilization tank, the top of the sterilization tank is sleeved with a sealing cover, a water adding valve is arranged at the bottom of the outer surface of the sterilization tank, a water inlet funnel is arranged at the top of the water adding valve, and a third servo motor is fixedly connected to the bottom of the sterilization tank; the output end of the third servo motor is fixedly connected with a threaded rod, and the middle of the bottom in the sterilization tank is fixedly connected with a fixed shaft. A plurality of groups of material containing screen frames can synchronously rotate and rotate for a period of time, and a first servo motor rotates reversely to drive the material containing screen frames to rotate reversely, so that the material containing screen frames irregularly rotate forwards and backwards back and forth in the sterilization tank, medicines in the material containing screen frames irregularly move, and the positions of the medicines are continuously changed; therefore, medicine sterilization is more thorough, the situation that medicine cannot be thoroughly sterilized due to long-time standing is avoided, medicine components are prevented from being damaged by residual bacteria, and economic losses are reduced.

The invention provides a method and a device for secondary filtration and re-removal of cholesterol ester after continuous blood purification and blood fat filtration, and belongs to the technical field of medical blood purification. According to the method and the device, the technology of combining enzymolysis, adsorption and membrane separation is adopted for residual CE in a CBP filtering product. The method comprises the following steps: firstly, decomposing CE into small molecules by using specific enzyme, and weakening the combination of CE and other components; residual impurities are further adsorbed through a high-performance adsorption material; and finally, efficient removal of CE is realized by virtue of a high-precision membrane separation technology, so that the residual quantity is reduced to be below a safety threshold value. Compared with a traditional technology, the problems that the CE-containing filtrate is high in recycling risk and low in resource utilization rate are effectively solved, the purity of a filtered product is remarkably improved, technical support is provided for industrial scenes such as plasma exchange, filtrate feedback, biopharmacy and extracorporeal circulation in the medical field, and the application prospect is wide. The safety and the resource utilization efficiency of the blood purification technology are promoted.

The invention relates to the technical field of biological medicine manufacturing, in particular to an environment-friendly and efficient Difelikefalin preparation method. According to the method, a solid-phase peptide synthesis technology is adopted, and the core is that a green mixed solvent system composed of 2-methyltetrahydrofuran and cyclopentyl methyl ether is used for comprehensively replacing traditional toxic solvents such as DMF and DCM. The method comprises the steps of resin swelling, Fmoc deprotection, amino acid coupling, peptide chain cutting, purification and freeze drying, a piperidine / 2-MeTHF solution is adopted in the deprotection, an optimized HATU / DIPEA activation system is adopted in the coupling reaction, a TFA / 2-MeTHF / water mixed solution is adopted in the cutting, and an ethanol-water chromatographic system is adopted in the purification. According to the invention, closed-loop circulation of the solvent is also realized, and 2-MeTHF and CPME are purified through rotary evaporation and reused in the synthesis process. According to the method, high purity and high yield of the product are guaranteed, production toxicity and environmental hazards are remarkably reduced, and the method has excellent industrial application prospects.

The sampling device comprises a sampling tank, a sealing cover and a protection piece, the sampling tank is arranged on the inner side of the protection piece, the sealing cover is arranged at the upper end of the sampling tank, the rear side of the upper end of the sealing cover is communicated with a guide pipe, the lower end of the rear side of the sampling tank is communicated with a conveying pipe, and the conveying pipe is communicated with the guide pipe. The protection piece comprises a supporting seat, a supporting frame, a supporting column and a connecting plate. The device has the beneficial effects that the sampling tank is placed above the supporting seat, the arc-shaped protection strip is attached to the back surface of the sampling tank, the supporting column is placed in the positioning cavity, and the mounting pin is inserted into the positioning cavity and extends into the through hole, so that the supporting column and the supporting frame are fixed; a supporting block and a rubber pad below the connecting plate are attached to a sealing cover above the sampling tank, so that the stability of the sampling tank during use is further improved, a user can directly take the sampling tank through a handle and the connecting plate without directly contacting the sampling tank, and the stability of the sampling tank is not influenced during movement.

The invention discloses a preparation method of a high-transparency TPE (thermoplastic elastomer) peristaltic pump pipe, and belongs to the technical field of high-molecular compounds. The preparation method comprises the following steps: blending high cis-1, 4-polybutadiene and polyethylene-polybutadiene to prepare a matrix phase; the method comprises the following steps: carrying out ester exchange reaction on dimethyl carbonate and polypropylene oxide glycol; then adding ethylene glycol as a chain extender to synthesize a polyurethane phase; carrying out melt blending on the two phases at a specific temperature, and adding dicumyl peroxide to initiate selective crosslinking; and finally, carrying out low-temperature and low-pressure extrusion molding to obtain the high-transparency TPE peristaltic pump pipe. By in-situ formation of an interpenetrating polymer network structure, nanoscale microphase separation is realized, so that the prepared pipe has high transparency, excellent fatigue resistance, excellent wear resistance and good chemical resistance at the same time. The method solves the industrial problem that a traditional peristaltic pump pipe is difficult to meet multiple high-performance requirements, and is suitable for the high-added-value fields such as biological pharmacy and precise instruments.

This invention belongs to the field of cryogenic concentration technology, specifically relating to a cryogenic concentration method. It involves freezing a dilute solution into a solid or solid-liquid mixture, using gas as an energy medium, and leveraging the solid structure of the frozen material's surface and interior. Heat is transferred to the frozen material by applying negative or positive pressure. Through dissolution and separation, solutions are collected in stages to obtain solutions of different concentrations. Solutions meeting the target concentration are transferred to the next stage; solutions not meeting the target concentration are reused to further increase the concentration. This method improves the efficiency of cryogenic concentration and separation purification, is simple to operate, and is suitable for applications in food, cosmetics, biopharmaceuticals, petrochemicals, metal processing, and environmental protection.

The invention relates to the technical field related to biopharmacy, in particular to a biopharmacy multiple inactivation device which comprises a pretreatment module and a multiple inactivation module. The multi-inactivation module comprises a supporting piece located at the lower end of the pretreatment module, and a pulsed electric field inactivation unit, a thermal inactivation unit and an ozone oxidation inactivation unit which are arranged on the supporting piece and are distributed in a circumferential array; and a flow path switching mechanism. The pulse electric field inactivation unit, the thermal inactivation unit and the ozone oxidation inactivation unit are adopted, corresponding inactivation treatment is carried out according to different classifications of liquid medicine, the functions are diversified, and the inactivation mode is not limited to a single inactivation mode; the flow path of the liquid medicine can be switched through the flow path switching mechanism, so that the pretreated liquid medicine is hermetically connected with any one of the pulsed electric field inactivation unit, the thermal inactivation unit and the ozone oxidation inactivation unit through the supporting piece, and corresponding liquid medicine inactivation treatment is carried out by using one inactivation unit in the multiple inactivation module as required.

The invention provides a drug combination composition for treating or / and improving attention impairment and application thereof, and relates to the technical field of biological medicine, the drug combination composition comprises isorhynchophylline and ginsenoside Rg1, and the isorhynchophylline and ginsenoside Rg1 are creatively combined to be used as a drug for treating or / and improving attention impairment. Researches show that the combination of isorhynchophylline and ginsenoside Rg1 has a more significant effect of treating or / and improving attention impairment than single isorhynchophylline or ginsenoside Rg1, provides a new strategy and idea for treating or / and improving attention impairment, and has very significant significance.

The utility model relates to the technical field of reaction kettles, and discloses a biopharmaceutical reaction kettle which comprises a reaction kettle body, lug seats are fixed on the outer side of the reaction kettle body, a blanking pipe is mounted at the bottom of the reaction kettle body, and supporting legs are fixed at the bottom of the reaction kettle body. Through the arrangement of the auxiliary cleaning mechanism, one end of the rotating frame pokes the moving rod to move back and forth, the anti-falling sliding plate drives the cast iron frame and the rubber column to move back and forth, the rubber column impacts the outer side of the discharging pipe back and forth, adhesion materials can be stripped in an auxiliary mode, and the situation that the purity of the next batch is affected due to residue degradation is reduced; by arranging the stabilizing mechanism, fixing between the mounting sleeve and the corresponding supporting leg is conveniently completed, at the moment, the corresponding faces of the outer shell and the metal support are attached, fixing between the outer shell and the metal support can be completed through bolts, the outer shell is easy to position and easy and convenient to assemble in the assembling process, and the assembling stability of the outer shell is improved.

The invention belongs to the technical field of biological medicine manufacturing, and particularly relates to preparation and application of collagen peptide with whitening activity. The preparation method of the collagen peptide with the whitening activity comprises the following steps: step A, inoculating bacillus subtilis into a culture medium containing a moringa oleifera leaf extracting solution, fermenting for 6-12 hours, inoculating aspergillus niger, continuously fermenting for 36-48 hours, sterilizing, centrifuging, and taking supernate to obtain moringa oleifera leaf fermentation liquor; and step B, scaling the fish skin, cleaning, drying and crushing, adding the moringa oleifera leaf fermentation liquor, reacting for 6-10 hours at the pH value of 6.0-7.0 and the temperature of 35-45 DEG C, and performing ultrafiltration, filtrate concentration and freeze-drying to obtain the collagen peptide. The preparation process has the advantages of low cost, greenness and high efficiency, and the prepared collagen peptide shows the activity of inhibiting tyrosinase and can be applied to preparation of skin care products or medicines with a whitening function.

The invention relates to the technical field of blister packaging, and discloses biopharmaceutical three-dosage-form integrated packaging equipment which comprises a machine table, a guide plate is arranged on the machine table, a mounting bottom plate is arranged above the guide plate, a visual detector is arranged on one side of the guide plate, and a plurality of dust removal seats distributed at equal intervals are arranged on the mounting bottom plate; a filter plate is fixed in the dust removal seat, a top plate is arranged below the filter plate, a circulation plate and two wedge-shaped abutting plates are arranged above the filter plate, the circulation plate abuts against the wedge-shaped abutting plates, abutting blocks are connected to the lower portions of the wedge-shaped abutting plates in a sliding mode, and limiting blocks are connected to the filter plate in a sliding mode; according to the pill packaging machine, pill detection and foreign matter detection are completed through one detection station, the detection efficiency is improved, the pill packaging time is shortened, and the overall packaging efficiency is improved.

The application discloses an antibody glycosylation modification regulation method, device and application, relates to the technical field of biopharmaceuticals and protein engineering, and realizes directional regulation of modification types, modification sites and modification proportions of N-glycan and O-glycan of the antibody through three core processes of constructing a glycosyltransferase engineering strain, optimizing a fermentation culture system and precisely regulating modification reaction conditions; solves the technical problems of low modification efficiency, poor specificity and insufficient product uniformity in the existing modification method, can improve the target glycan modification proportion to more than 90%, the modification product purity is greater than or equal to 98%, is suitable for glycosylation modification optimization of therapeutic monoclonal antibodies, bispecific antibodies and antibody drug conjugates, significantly improves the biological activity and pharmacokinetic performance of the antibody, wherein the ADCC activity is improved by 3-5 times, and the CDC activity is improved by 2-4 times, and has the advantages of strong controllability, good adaptability to large-scale production and high cost-effectiveness.

The invention relates to the technical field of biological medicine preparations, and discloses a calcium, vitamin D and vitamin K. A content composition of the soft capsule comprises a microgel skeleton composed of amphiphilic polypeptide calcium ions and vitamin oil drops, the hydrophobic end of amphiphilic polypeptide adsorbs the oil drops, and the hydrophobic end of the amphiphilic polypeptide adsorbs the vitamin oil drops. A hydrophilic end of the composition is bridged by calcium ions to form a network, the composition also comprises a histidine-enriched polypeptide which can form a protective shielding layer on the surface of a skeleton under acidic pH, the calcium ions are converted from a chemical destroyer to a structural stabilizer, and a static synergistic system is constructed, so that the contact degradation of calcium and vitamins is eliminated, and the stability of the composition is improved. The performance contradiction between the high calcium content and the vitamin stability is avoided, and the endophytic environmental adaptability of the composition is improved.